VCF is offering Charité scientists and external academic institutions new modified AAV serotypes which enable the virus to cross the blood brain barrier. By modifying the capsid protein noninvasive gene delivery can be done. You can order new viruses via our online tool.
Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Chan KY et al., Nat Neurosci. 2017 Aug;20(8):1172-1179.
Back to Overview